- Home
- ANNX vs CADL Comparison
ANNX vs CADL Comparison
Compare ANNX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- CADL
- Stock Information
- Founded
- ANNX 2011
- CADL 1999
- Country
- ANNX United States
- CADL United States
- Employees
- ANNX N/A
- CADL N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- ANNX Health Care
- CADL Health Care
- Exchange
- ANNX Nasdaq
- CADL Nasdaq
- Market Cap
- ANNX 263.3M
- CADL 315.1M
- IPO Year
- ANNX 2020
- CADL 2021
- Fundamental
- Price
- ANNX $2.42
- CADL $6.00
- Analyst Decision
- ANNX Strong Buy
- CADL Strong Buy
- Analyst Count
- ANNX 4
- CADL 5
- Target Price
- ANNX $12.50
- CADL $21.40
- AVG Volume (30 Days)
- ANNX 1.7M
- CADL 990.4K
- Earning Date
- ANNX 08-11-2025
- CADL 08-12-2025
- Dividend Yield
- ANNX N/A
- CADL N/A
- EPS Growth
- ANNX N/A
- CADL N/A
- EPS
- ANNX N/A
- CADL N/A
- Revenue
- ANNX N/A
- CADL N/A
- Revenue This Year
- ANNX N/A
- CADL N/A
- Revenue Next Year
- ANNX N/A
- CADL N/A
- P/E Ratio
- ANNX N/A
- CADL N/A
- Revenue Growth
- ANNX N/A
- CADL N/A
- 52 Week Low
- ANNX $1.29
- CADL $3.79
- 52 Week High
- ANNX $7.85
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- ANNX 47.32
- CADL 47.61
- Support Level
- ANNX $2.29
- CADL $6.11
- Resistance Level
- ANNX $2.62
- CADL $6.40
- Average True Range (ATR)
- ANNX 0.17
- CADL 0.34
- MACD
- ANNX -0.01
- CADL -0.11
- Stochastic Oscillator
- ANNX 37.74
- CADL 6.67
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.